Safety profile of immune checkpoint inhibitors versus sorafenib as first-line treatment in advanced hepatocellular carcinoma: A meta-analysis of randomized controlled trials.

被引：0
|
作者：
Rizzo, Alessandro [1 ]
Frega, Giorgio [2 ]
Ricci, Angela Dalia [1 ]
Palloni, Andrea [1 ]
Tavolari, Simona [3 ]
Brandi, Giovanni [2 ]
机构：
[1] Univ Bologna, St Orsola Malpighi Hosp, Dept Expt Diagnost & Specialty Med DIMES, Bologna, Italy
[2] Policlin S Orsola Malpighi Hosp, Dept Expt Diagnost & Specialty Med, Bologna, Italy
[3] Univ Bologna, Bologna, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 03期
关键词：
D O I：
10.1200/JCO.2021.39.3_suppl.315
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
315
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Efficacy and safety of lenvatinib versus sorafenib in first-line treatment of advanced hepatocellular carcinoma: A meta-analysis
    Luo, Jia
    Gao, Benjian
    Lin, Zhiyu
    Fan, Hua
    Ma, Wen
    Yu, Danfei
    Yang, Qian
    Tian, Jing
    Yang, Xiaoli
    Li, Bo
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [2] Immune-Based Combinations versus Sorafenib as First-Line Treatment for Advanced Hepatocellular Carcinoma: A Meta-Analysis
    Rizzo, Alessandro
    Ricci, Angela Dalia
    Fanizzi, Annarita
    Massafra, Raffaella
    De Luca, Raffaele
    Brandi, Giovanni
    CURRENT ONCOLOGY, 2023, 30 (01) : 749 - 757
  • [3] Efficacy and Safety of Immune Checkpoint Inhibitors Combined With Chemotherapy as First-line Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma: A Network Meta-analysis of Randomized Controlled Trials
    Sun, Hong
    Bu, Fengjiao
    Li, Ling
    Zhang, Xiuwen
    Xin, Xiu
    Yan, Jingchao
    Huang, Taomin
    ANNALS OF PHARMACOTHERAPY, 2024, 58 (04) : 349 - 359
  • [4] Immunotherapy versus tyrosine kinase inhibitors in advanced hepatocellular carcinoma in first-line setting: A systematic review and meta-analysis of randomized controlled trials
    Carolina Marin Comini, Ana Carolina
    de Sousa, Isadora Martins
    Abrahao Reis, Pedro Cotta
    Carvalho, Bruno Murad
    Guedes Camandaroba, Marcos Pedro
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [5] Combination therapy with checkpoint inhibitors for first-line treatment of advanced renal cell carcinoma: A systematic review and meta-analysis of randomized controlled trials
    Thein, K. Z.
    Mogollon-Duffo, F.
    Swarup, S.
    Sultan, A.
    Yendala, R.
    Jahan, N.
    Quirch, M.
    Ball, S.
    Htut, T. Win
    D'Cunha, N.
    Rehman, S.
    Hardwicke, F.
    Awasthi, S.
    Tijani, L.
    ANNALS OF ONCOLOGY, 2019, 30
  • [6] Selection of first-line systemic therapies for advanced hepatocellular carcinoma: A network meta-analysis of randomized controlled trials
    Yue Han
    Wei-Hua Zhi
    Fei Xu
    Chen-Bo Zhang
    Xiao-Qian Huang
    Jian-Feng Luo
    World Journal of Gastroenterology, 2021, 27 (19) : 2415 - 2433
  • [7] Selection of first-line systemic therapies for advanced hepatocellular carcinoma: A network meta-analysis of randomized controlled trials
    Han, Yue
    Zhi, Wei-Hua
    Xu, Fei
    Zhang, Chen-Bo
    Huang, Xiao-Qian
    Luo, Jian-Feng
    WORLD JOURNAL OF GASTROENTEROLOGY, 2021, 27 (19) : 2415 - 2433
  • [8] Comparison of checkpoint inhibitor-based regimens as first-line therapy in advanced hepatocellular carcinoma: A Frequentist Network meta-analysis of randomized clinical trials.
    Ali, Muhammad Ashar
    Aiman, Wajeeha
    Ali, Mukarram Jamat
    Anwar, Muhammad Yasir
    Shaaban, Hamid Salim
    Guron, Gunwant K.
    Maroules, Michael
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [9] Lenvatinib versus sorafenib as first-line therapy of advanced hepatocellular carcinoma: a systematic review and meta-analysis
    Facciorusso, Antonio
    Tartaglia, Nicola
    Villani, Rosanna
    Serviddio, Gaetano
    Ramai, Daryl
    Mohan, Babu P.
    Chandan, Saurabh
    Abd El Aziz, Mohamed A.
    Evangelista, Jessica
    Cotsoglou, Christian
    Ambrosi, Antonio
    AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH, 2021, 13 (04): : 2379 - 2387
  • [10] Treatment-related adverse events of first-line immunotherapy versus sorafenib for advanced hepatocellular carcinoma: a meta-analysis
    Rizzo, Alessandro
    Carloni, Riccardo
    Ricci, Angela Dalia
    Cusmai, Antonio
    Laforgia, Mariarita
    Calabro, Concetta
    Ungaro, Valentina
    Oreste, Donato
    Sollitto, Mario
    Palmiotti, Gennaro
    Brandi, Giovanni
    EXPERT OPINION ON DRUG SAFETY, 2023, 22 (04) : 323 - 329
12345